Weihua Zhao1, David R Beers1, Kristopher G Hooten2, Douglas H Sieglaff3, Aijun Zhang4, Shanker Kalyana-Sundaram5, Christopher M Traini5, Wendy S Halsey5, Ashley M Hughes5, Ganesh M Sathe5, George P Livi5, Guo-Huang Fan6, Stanley H Appel1. 1. Department of Neurology, Peggy and Gary Edwards ALS Laboratory, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston, Texas. 2. Department of Neurosurgery, University of Florida, Gainesville. 3. Texas Genomic Medicine Research Program, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston, Texas. 4. Department of Medicine, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston, Texas. 5. Target Sciences at GlaxoSmithKline R&D, Collegeville, Pennsylvania. 6. GlaxoSmithKline R&D, Shanghai, China.
Abstract
Importance: Amyotrophic lateral sclerosis (ALS) is a common adult-onset neurodegenerative disease characterized by selective loss of upper and lower motor neurons. Patients with ALS have persistent peripheral and central inflammatory responses including abnormally functioning T cells and activated microglia. However, much less is known about the inflammatory gene profile of circulating innate immune monocytes in these patients. Objective: To characterize the transcriptomics of peripheral monocytes in patients with ALS. Design, Setting, and Participants: Monocytes were isolated from peripheral blood of 43 patients with ALS and 22 healthy control individuals. Total RNA was extracted from the monocytes and subjected to deep RNA sequencing, and these results were validated by quantitative reverse transcription polymerase chain reaction. Main Outcomes and Measures: The differential expressed gene signatures of these monocytes were identified using unbiased RNA sequencing strategy for gene expression profiling. Results: The demographics between the patients with ALS (mean [SD] age, 58.8 [1.57] years; 55.8% were men and 44.2% were women; 90.7% were white, 4.65% were Hispanic, 2.33% were black, and 2.33% were Asian) and control individuals were similar (mean [SD] age, 57.6 [2.15] years; 50.0% were men and 50.0% were women; 90.9% were white, none were Hispanic, none were black, and 9.09% were Asian). RNA sequencing data from negative selected monocytes revealed 233 differential expressed genes in ALS monocytes compared with healthy control monocytes. Notably, ALS monocytes demonstrated a unique inflammation-related gene expression profile, the most prominent of which, including IL1B, IL8, FOSB, CXCL1, and CXCL2, were confirmed by quantitative reverse transcription polymerase chain reaction (IL8, mean [SE], 1.00 [0.18]; P = .002; FOSB, 1.00 [0.21]; P = .009; CXCL1, 1.00 [0.14]; P = .002; and CXCL2, 1.00 [0.11]; P = .01). Amyotrophic lateral sclerosis monocytes from rapidly progressing patients had more proinflammatory DEGs than monocytes from slowly progressing patients. Conclusions and Relevance: Our data indicate that ALS monocytes are skewed toward a proinflammatory state in the peripheral circulation and may play a role in ALS disease progression, especially in rapidly progressing patients. This increased inflammatory response of peripheral immune cells may provide a potential target for disease-modifying therapy in patients with ALS.
Importance: Amyotrophic lateral sclerosis (ALS) is a common adult-onset neurodegenerative disease characterized by selective loss of upper and lower motor neurons. Patients with ALS have persistent peripheral and central inflammatory responses including abnormally functioning T cells and activated microglia. However, much less is known about the inflammatory gene profile of circulating innate immune monocytes in these patients. Objective: To characterize the transcriptomics of peripheral monocytes in patients with ALS. Design, Setting, and Participants: Monocytes were isolated from peripheral blood of 43 patients with ALS and 22 healthy control individuals. Total RNA was extracted from the monocytes and subjected to deep RNA sequencing, and these results were validated by quantitative reverse transcription polymerase chain reaction. Main Outcomes and Measures: The differential expressed gene signatures of these monocytes were identified using unbiased RNA sequencing strategy for gene expression profiling. Results: The demographics between the patients with ALS (mean [SD] age, 58.8 [1.57] years; 55.8% were men and 44.2% were women; 90.7% were white, 4.65% were Hispanic, 2.33% were black, and 2.33% were Asian) and control individuals were similar (mean [SD] age, 57.6 [2.15] years; 50.0% were men and 50.0% were women; 90.9% were white, none were Hispanic, none were black, and 9.09% were Asian). RNA sequencing data from negative selected monocytes revealed 233 differential expressed genes in ALS monocytes compared with healthy control monocytes. Notably, ALS monocytes demonstrated a unique inflammation-related gene expression profile, the most prominent of which, including IL1B, IL8, FOSB, CXCL1, and CXCL2, were confirmed by quantitative reverse transcription polymerase chain reaction (IL8, mean [SE], 1.00 [0.18]; P = .002; FOSB, 1.00 [0.21]; P = .009; CXCL1, 1.00 [0.14]; P = .002; and CXCL2, 1.00 [0.11]; P = .01). Amyotrophic lateral sclerosis monocytes from rapidly progressing patients had more proinflammatory DEGs than monocytes from slowly progressing patients. Conclusions and Relevance: Our data indicate that ALS monocytes are skewed toward a proinflammatory state in the peripheral circulation and may play a role in ALS disease progression, especially in rapidly progressing patients. This increased inflammatory response of peripheral immune cells may provide a potential target for disease-modifying therapy in patients with ALS.
Authors: Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo Journal: Nature Date: 2006-04-30 Impact factor: 49.962
Authors: Lisa Zondler; Kathrin Müller; Samira Khalaji; Corinna Bliederhäuser; Wolfgang P Ruf; Veselin Grozdanov; Meinolf Thiemann; Katrin Fundel-Clemes; Axel Freischmidt; Karlheinz Holzmann; Benjamin Strobel; Patrick Weydt; Anke Witting; Dietmar R Thal; Anika M Helferich; Bastian Hengerer; Kay-Eberhard Gottschalk; Oliver Hill; Michael Kluge; Albert C Ludolph; Karin M Danzer; Jochen H Weishaupt Journal: Acta Neuropathol Date: 2016-02-24 Impact factor: 17.088
Authors: Oleg Butovsky; Mark P Jedrychowski; Ron Cialic; Susanne Krasemann; Gopal Murugaiyan; Zain Fanek; David J Greco; Pauline M Wu; Camille E Doykan; Olga Kiner; Robert J Lawson; Matthew P Frosch; Nathalie Pochet; Rachid El Fatimy; Anna M Krichevsky; Steven P Gygi; Hans Lassmann; James Berry; Merit E Cudkowicz; Howard L Weiner Journal: Ann Neurol Date: 2014-11-27 Impact factor: 10.422
Authors: J Kuhle; R L P Lindberg; A Regeniter; M Mehling; A J Steck; L Kappos; A Czaplinski Journal: Eur J Neurol Date: 2009-02-19 Impact factor: 6.089
Authors: Yanzhu Lin; Kseniya Golovnina; Zhen-Xia Chen; Hang Noh Lee; Yazmin L Serrano Negron; Hina Sultana; Brian Oliver; Susan T Harbison Journal: BMC Genomics Date: 2016-01-05 Impact factor: 3.969
Authors: Oleg Butovsky; Shafiuddin Siddiqui; Galina Gabriely; Amanda J Lanser; Ben Dake; Gopal Murugaiyan; Camille E Doykan; Pauline M Wu; Reddy R Gali; Lakshmanan K Iyer; Robert Lawson; James Berry; Anna M Krichevsky; Merit E Cudkowicz; Howard L Weiner Journal: J Clin Invest Date: 2012-08-06 Impact factor: 14.808
Authors: Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger Journal: Immunity Date: 2006-02 Impact factor: 31.745
Authors: Björn F Vahsen; Elizabeth Gray; Alexander G Thompson; Olaf Ansorge; Daniel C Anthony; Sally A Cowley; Kevin Talbot; Martin R Turner Journal: Nat Rev Neurol Date: 2021-04-29 Impact factor: 42.937
Authors: Nayana Gaur; Elena Huss; Tino Prell; Robert Steinbach; Joel Guerra; Akash Srivastava; Otto W Witte; Julian Grosskreutz Journal: Front Neurol Date: 2021-05-14 Impact factor: 4.003